{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:00:20Z","timestamp":1781690420595,"version":"3.54.5"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Post\u2013liver transplant complications\u2014cancer, infections, and renal dysfunction\u2014impose substantial clinical and economic impact on recipients. This study evaluated clinical impacts and cost-effectiveness of adding everolimus (EVR) to a calcineurin inhibitor (CNI)-based regimen in liver transplant recipients, aiming to identify how co-occurring major complications affect cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We conducted a cohort analysis and a cost-utility analysis, dividing recipients into CNI with and without EVR groups. We calculated adjusted hazard ratios (HRs) for the risk of cancer and posttransplant infection with EVR combination therapy using a Cox regression model. A Markov model that captured the co-occurrence of liver disease, infection, and renal dysfunction was constructed to estimate costs and quality-adjusted life years (QALYs) and compare the incremental cost-effectiveness ratio (ICER) of adding EVR to CNI. A hypothetical cohort of 10\u2009000 liver transplant recipients aged 55 y was simulated during 30 y.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>The addition of EVR significantly reduced the risk of cancer (HR 0.435; 95% confidence interval 0.279-0.678) while increasing the infection risk in subsequent years (HR 1.468; 95% confidence interval 1.053-2.045). Cost-utility analysis demonstrated the CNI with EVR strategy was cost-effective, with an ICER of US$5298\/QALY, well below the $25\u2009000\/QALY threshold. In analyses quantifying how co-occurring events shift value, the ICER was $9307\/QALY when limited to liver disease, decreased to $4363\/QALY with renal dysfunction included, and increased to $10\u2009464\/QALY when infection was added.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Overall, CNI with EVR regimen in liver transplant remained cost-effective across co-occurring outcomes and perspectives, supporting risk-benefit balancing across cancer, posttransplant infection, and renal function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005688","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T16:00:28Z","timestamp":1776960028000},"page":"e1437-e1446","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Impact and Cost-effectiveness of Everolimus Combination Therapy in Liver Transplant Recipients: Focus on the Risk of Cancer, Infection, and Renal Function"],"prefix":"10.1097","volume":"110","author":[{"given":"Suk-Chan","family":"Jang","sequence":"first","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea."},{"name":"College of Pharmacy, University of Florida, Gainesville, Florida, United States."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-Ae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Lin","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Sahmyook University, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-Kyung","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"R1-20260616","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation\u2014PROTECT.","volume":"12","author":"Fischer","year":"2012","journal-title":"Am J Transplant"},{"key":"R2-20260616","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"R3-20260616","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/ajt.12280","article-title":"Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study.","volume":"13","author":"Saliba","year":"2013","journal-title":"Am J Transplant"},{"key":"R4-20260616","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0000000000000555","article-title":"Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study.","volume":"99","author":"Fischer","year":"2015","journal-title":"Transplantation"},{"key":"R5-20260616","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ajt.2025.01.005","article-title":"Association between everolimus combination therapy and cancer risk after liver transplantation: a nationwide population-based quasi-cohort study.","volume":"25","author":"Jang","year":"2025","journal-title":"Am J Transplant"},{"key":"R6-20260616","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL Clinical Practice Guidelines: liver transplantation.","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R7-20260616","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity.","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R8-20260616","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3350\/cmh.2021.0038","article-title":"Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma.","volume":"27","author":"Kang","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"R9-20260616","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4254\/wjh.v9.i23.990","article-title":"Use of everolimus in liver transplantation.","volume":"9","author":"Yee","year":"2017","journal-title":"World J Hepatol"},{"key":"R10-20260616","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"38","author":"Husereau","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"key":"R11-20260616","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0168-8510(94)00669-6","article-title":"Health for all in the Republic of Korea: one country\u2019s experience with implementing universal health care.","volume":"31","author":"Peabody","year":"1995","journal-title":"Health Policy"},{"key":"R12-20260616","doi-asserted-by":"crossref","first-page":"906211","DOI":"10.3389\/fphar.2022.906211","article-title":"Optimal indicator of death for using real-world cancer patients\u2019 data from the healthcare system.","volume":"13","author":"Jang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R13-20260616","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/ciz1113","article-title":"Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss Transplant Cohort Study.","volume":"71","author":"van Delden","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R14-20260616","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.healun.2022.08.001","article-title":"Clinical impact and economic burden of post-transplant infections following heart transplantation: a retrospective nationwide cohort study.","volume":"41","author":"Jang","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"R15-20260616","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2018.12.009","article-title":"Age and liver transplantation.","volume":"70","author":"Durand","year":"2019","journal-title":"J Hepatol"},{"key":"R17-20260616","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1136\/gutjnl-2020-321309","article-title":"Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.","volume":"70","author":"Kim","year":"2021","journal-title":"Gut"},{"key":"R18-20260616","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"R19-20260616","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3350\/cmh.2021.0236","article-title":"A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: a societal perspective.","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"R20-20260616","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40273-019-00864-8","article-title":"Value in hepatitis C virus treatment: a patient-centered cost-effectiveness analysis.","volume":"38","author":"Mattingly","year":"2020","journal-title":"PharmacoEcon"},{"key":"R21-20260616","doi-asserted-by":"crossref","first-page":"e0255655","DOI":"10.1371\/journal.pone.0255655","article-title":"Association between hospital liver transplantation volume and mortality after liver re-transplantation.","volume":"16","author":"Oh","year":"2021","journal-title":"PLoS One"},{"key":"R22-20260616","doi-asserted-by":"crossref","first-page":"e005376","DOI":"10.1136\/bmjopen-2014-005376","article-title":"The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high\/very high drinking risk levels: a Markov model.","volume":"4","author":"Laramee","year":"2014","journal-title":"BMJ Open"},{"key":"R23-20260616","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20133.","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"key":"R25-20260616","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40273-014-0132-3","article-title":"How to estimate productivity costs in economic evaluations.","volume":"32","author":"Krol","year":"2014","journal-title":"PharmacoEcon"},{"key":"R26-20260616","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40273-020-00986-4","article-title":"Use of productivity loss\/gain in cost-effectiveness analyses for drugs: a systematic review.","volume":"39","author":"Yuasa","year":"2021","journal-title":"PharmacoEcon"},{"key":"R28-20260616","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1080\/13696998.2016.1179199","article-title":"Cost-effectiveness of everolimus plus reduced tacrolimus in de novo liver-recipients in the Italian setting.","volume":"19","author":"Bianic","year":"2016","journal-title":"J Med Econ"},{"key":"R31-20260616","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhep.2004.10.026","article-title":"Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance.","volume":"42","author":"Ahn","year":"2005","journal-title":"J Hepatol"},{"key":"R32-20260616","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","article-title":"Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.","volume":"11","author":"Pichon-Riviere","year":"2023","journal-title":"Lancet Glob Health"},{"key":"R33-20260616","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ajt.14208","article-title":"Infection in organ transplantation.","volume":"17","author":"Fishman","year":"2017","journal-title":"Am J Transplant"},{"key":"R34-20260616","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/ajt.14623","article-title":"Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study.","volume":"18","author":"Jeng","year":"2018","journal-title":"Am J Transplant"},{"key":"R35-20260616","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ajt.12615","article-title":"Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation.","volume":"14","author":"Sterneck","year":"2014","journal-title":"Am J Transplant"},{"key":"R36-20260616","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cgh.2017.06.024","article-title":"Cost effectiveness of pre- vs post-liver transplant hepatitis C treatment with direct-acting antivirals.","volume":"16","author":"Samur","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R37-20260616","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/13696998.2016.1189921","article-title":"A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.","volume":"19","author":"Muduma","year":"2016","journal-title":"J Med Econ"},{"key":"R38-20260616","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ajt.16155","article-title":"Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients.","volume":"21","author":"Asleh","year":"2021","journal-title":"Am J Transplant"},{"key":"R39-20260616","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/TP.0000000000004336","article-title":"Mammalian target of rapamycin inhibitors and kidney function after thoracic transplantation: a systematic review and recommendations for management of lung transplant recipients.","volume":"107","author":"Schmucki","year":"2023","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:45Z","timestamp":1781647245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005688","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]}}}